| Bioactivity | Psoralidin is a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties[1]. Psoralidin significantly downregulates NOTCH1 signaling. Psoralidin also greatly induces ROS generation[2]. | ||||||||||||
| Invitro | Three breast cancer cell (BCC)populations (ALDH- cells, ALDH+ cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25 μM; 24 hours) with IC50s ranging from 18 to 21 μM; however, the MCF-12A cells were resistant to Psoralidin[2]. Psoralidin (30 μM; 24 hours) results in a significant induction of apoptosis for ALDH- cells, ALDH+ cells, and commercial BCSCs[2].Psoralidin treatment also downregulates NOTCH1 expression in both ALDH- and ALDH+ cells[2]. Cell Viability Assay[2] Cell Line: | ||||||||||||
| Name | Psoralidin | ||||||||||||
| CAS | 18642-23-4 | ||||||||||||
| Formula | C20H16O5 | ||||||||||||
| Molar Mass | 336.34 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|